ALRN
|Aileron Therapeutics Inc
NASDAQ
USD
|%
Current Price
Change
(%)
P/E Ratio
Dividend Yield
Market Cap
45.72M
Volume
Open
Previous Close
52-Week High
USD 4.40
52-Week Low
USD 1.61
About Aileron Therapeutics Inc
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleu...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. James Brian Windsor Ph.D.
Employees:15
Headquarters:Austin, USA
Website:www.aileronrx.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions